thrombosis with thrombocytopenia syndrome

thrombosis with thrombocytopenia syndrome
Name	Thrombosis with Thrombocytopenia Syndrome
Synonyms	Vaccine-induced immune thrombotic thrombocytopenia (VITT), Thrombotic thrombocytopenic syndrome
Field	Hematology, Immunology, Vaccinology
Symptoms	Severe headache, shortness of breath, abdominal pain, neurological deficit
Complications	Cerebral venous sinus thrombosis, splanchnic vein thrombosis, pulmonary embolism
Onset	5 to 30 days post-vaccination
Risks	Administration of adenoviral vector COVID-19 vaccines (e.g., Vaxzevria, Janssen)
Diagnosis	Complete blood count, D-dimer test, PF4 ELISA, imaging studies
Treatment	Intravenous immunoglobulin, non-heparin anticoagulants (e.g., argatroban, fondaparinux), avoid heparin and platelet transfusion
Prognosis	Variable, high mortality if untreated

thrombosis with thrombocytopenia syndrome. Thrombosis with thrombocytopenia syndrome is a rare but serious condition characterized by the formation of blood clots alongside a low platelet count. It gained significant medical and public attention following its association with certain adenoviral vector-based COVID-19 vaccines. The syndrome shares pathophysiological similarities with heparin-induced thrombocytopenia but occurs in a distinct context. Prompt recognition and specific management are critical due to the high risk of severe thrombotic complications.

Definition and overview

Thrombosis with thrombocytopenia syndrome is defined by the concurrent presence of venous or arterial thrombosis and thrombocytopenia, typically occurring within a specific timeframe after an inciting trigger. The condition is mediated by an immune response that leads to platelet activation and consumptive coagulopathy. Major health agencies, including the World Health Organization and the Centers for Disease Control and Prevention, have issued specific case definitions to aid surveillance and diagnosis. It is considered distinct from other thrombotic microangiopathies like thrombotic thrombocytopenic purpura or disseminated intravascular coagulation.

Causes and pathophysiology

The primary identified cause is immunization with specific COVID-19 vaccines utilizing adenoviral vector technology, notably the Vaxzevria developed by the University of Oxford and AstraZeneca, and the Janssen vaccine by Janssen Pharmaceuticals. The proposed mechanism involves the development of pathogenic antibodies against platelet factor 4 (PF4). These antibodies form large immune complexes that activate platelets via their FcγRIIa receptors, leading to widespread platelet aggregation and thrombin generation. This process results in both clot formation and platelet consumption, mirroring the pathology of heparin-induced thrombocytopenia but without prior heparin exposure.

Clinical presentation and diagnosis

Patients typically present 5 to 30 days post-vaccination with symptoms related to thrombosis. Common presentations include severe headache from cerebral venous sinus thrombosis, abdominal pain from splanchnic vein thrombosis (e.g., in the portal vein or hepatic vein), chest pain from pulmonary embolism, or limb swelling from deep vein thrombosis. Diagnosis requires a high index of suspicion and involves confirming thrombocytopenia via complete blood count, detecting elevated D-dimer, and identifying anti-PF4 antibodies using a PF4 ELISA. Imaging studies such as computed tomography angiography or magnetic resonance venography are essential to locate thromboses.

Treatment and management

First-line treatment involves administering high-dose intravenous immunoglobulin to block pathogenic antibody activity. Anticoagulation with non-heparin agents like argatroban, fondaparinux, or direct oral anticoagulants is crucial. Critically, heparin and platelet transfusions are contraindicated as they may exacerbate thrombosis. Management often requires a multidisciplinary team in settings like the intensive care unit. Guidance from bodies like the American Society of Hematology and the International Society on Thrombosis and Haemostasis has been instrumental in standardizing care protocols.

Epidemiology and risk factors

The syndrome is exceedingly rare, with estimated incidence rates following adenoviral vector vaccines reported by agencies like the European Medicines Agency and the Medicines and Healthcare products Regulatory Agency. Cases have been reported globally, including in the United Kingdom, the European Union, Australia, and Canada. Identified risk factors may include younger age, with a higher observed incidence in individuals under 60, and possibly female sex, though cases occur across demographics. No specific genetic predispositions, such as variations in the PF4 gene, have been conclusively established.

History and nomenclature

The syndrome was first widely recognized in early 2021 following reports from Austria and Norway of unusual thrombotic events after vaccination with Vaxzevria. Initial investigations were led by teams at the Greifswald University Hospital in Germany and the Oslo University Hospital. The condition has been termed vaccine-induced immune thrombotic thrombocytopenia by the International Society on Thrombosis and Haemostasis and thrombosis with thrombocytopenia syndrome by the Centers for Disease Control and Prevention. Its discovery prompted regulatory reviews by the European Medicines Agency and temporary suspensions of vaccine use in several countries, marking a significant event in modern vaccinology and pharmacovigilance.

Category:Blood disorders Category:Adverse effects of drugs Category:COVID-19 pandemic